Dupixent Approval In Japan Expands Treatment Of Bronchial Asthma To Children Aged 6 To 11 Years Following Global Phase 3 VOYAGE And EXCURSION Data

Sanofi and Regeneron's Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma

• Approval based on global phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function compared to placebo (by 4.68% to 5.32%)   
• Dupixent is the first and only biologic medicine to demonstrate improved lung function in this young patient group in a randomized phase 3 study, and inhibits IL-4 and IL-13, two key and central drivers of type 2 inflammation